Home › Funds › Michelson Medical Research Foundation, Inc. › GXC
Michelson Medical Research Foundation, Inc. position in GXC
SPDR INDEX SHS FDS
Michelson Medical Research Foundation, Inc. reported holding 16,750 shares of GXC (SPDR INDEX SHS FDS) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 1.29% of its reported portfolio and ranking #20 among its reported holdings. Michelson Medical Research Foundation, Inc. has disclosed GXC holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Michelson Medical Research Foundation, Inc.'s GXC position evolved
Michelson Medical Research Foundation, Inc. first disclosed a stake in GXC in Q4 2023 at 16,750 shares (US$1.1M). The position peaked in Q3 2025 at 16,750 shares, worth US$1.8M. Across 12 filings, Michelson Medical Research Foundation, Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 16,750 shares valued at US$1.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 16.75K | $1.14M | New |
| Q1 2024 | 16.75K | $1.10M | Hold |
| Q2 2024 | 16.75K | $1.15M | Hold |
| Q3 2024 | 16.75K | $1.38M | Hold |
| Q4 2024 | 16.75K | $1.27M | Hold |
| Q1 2025 | 16.75K | $1.44M | Hold |
| Q2 2025 | 16.75K | $1.47M | Hold |
| Q3 2025 | 16.75K | $1.76M | Hold |
| Q4 2025 | 16.75K | $1.62M | Hold |
| Q1 2026 | 16.75K | $1.56M | Hold |
| Q2 2026 | 16.75K | $1.45M | Hold |
| Q3 2026 | 16.75K | $1.45M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GXC and 13F data
GXC (SPDR INDEX SHS FDS) is a company whose sector is not yet classified in our data. 22 other funds we track also report a position in GXC — the largest reported positions include OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC (US$17.5M), swisspartners Advisors Ltd (US$12.9M), Prism Advisors, Inc. (US$7.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GXC
- OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC 201.35K sh · $17.47M · Q3 2026
- swisspartners Advisors Ltd 149.23K sh · $12.93M · Q3 2026
- Prism Advisors, Inc. 93.61K sh · $7.95M · Q3 2026
- Mittelman Wealth Management 27.16K sh · $2.36M · Q3 2026
More on Michelson Medical Research Foundation, Inc.
FAQ
How long has Michelson Medical Research Foundation, Inc. held GXC?
Michelson Medical Research Foundation, Inc. has disclosed GXC holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Michelson Medical Research Foundation, Inc.'s current position in GXC?
As of Q3 2026, Michelson Medical Research Foundation, Inc. holds 16.75K shares of GXC (SPDR INDEX SHS FDS), valued at $1.45M, representing 1.29% of its reported portfolio and ranking #20.
Has Michelson Medical Research Foundation, Inc. been buying or selling GXC?
In the latest 13F filing (Q3 2026), Michelson Medical Research Foundation, Inc. held unchanged its position in GXC. The position peaked in Q3 2025 at 16.75K shares.
Which other funds hold GXC?
Other major institutional holders of GXC include OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC, swisspartners Advisors Ltd, Prism Advisors, Inc., among 22 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.